Wall Street analysts expect that IQVIA Holdings Inc. (NYSE:IQV) will post sales of $3.17 billion for the current quarter, according to Zacks Investment Research. Nine analysts have issued estimates for IQVIA’s earnings, with the highest sales estimate coming in at $3.19 billion and the lowest estimate coming in at $3.16 billion. IQVIA posted sales of $2.75 billion during the same quarter last year, which indicates a positive year over year growth rate of 15.3%. The firm is expected to issue its next earnings report on Tuesday, April 27th.
According to Zacks, analysts expect that IQVIA will report full year sales of $12.81 billion for the current year, with estimates ranging from $12.75 billion to $12.89 billion. For the next fiscal year, analysts anticipate that the company will post sales of $13.91 billion, with estimates ranging from $13.66 billion to $14.39 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for IQVIA.
IQVIA (NYSE:IQV) last announced its quarterly earnings results on Wednesday, February 10th. The medical research company reported $2.11 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.00 by $0.11. IQVIA had a net margin of 1.61% and a return on equity of 18.03%. The firm had revenue of $3.30 billion during the quarter, compared to analysts’ expectations of $3.14 billion. During the same period in the prior year, the company posted $1.74 EPS. The company’s revenue was up 13.9% on a year-over-year basis.
Shares of NYSE:IQV traded up $0.70 during trading on Thursday, reaching $190.84. The stock had a trading volume of 45,558 shares, compared to its average volume of 924,720. The firm’s fifty day moving average is $186.50 and its 200 day moving average is $170.55. The company has a debt-to-equity ratio of 2.00, a quick ratio of 1.12 and a current ratio of 1.12. IQVIA has a 52 week low of $81.79 and a 52 week high of $199.99. The stock has a market cap of $36.50 billion, a price-to-earnings ratio of 208.95, a P/E/G ratio of 2.26 and a beta of 1.41.
In related news, Director John G. Danhakl bought 63,451 shares of the company’s stock in a transaction on Wednesday, December 23rd. The stock was acquired at an average cost of $176.95 per share, for a total transaction of $11,227,654.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 6.00% of the stock is currently owned by company insiders.
Institutional investors have recently made changes to their positions in the business. Alpha Paradigm Partners LLC bought a new stake in IQVIA during the fourth quarter valued at approximately $28,000. International Assets Investment Management LLC bought a new stake in IQVIA during the fourth quarter valued at approximately $31,000. Jeppson Wealth Management LLC bought a new stake in IQVIA during the third quarter valued at approximately $32,000. Safeguard Investment Advisory Group LLC purchased a new position in shares of IQVIA during the fourth quarter worth approximately $34,000. Finally, TD Ameritrade Investment Management LLC purchased a new position in shares of IQVIA during the fourth quarter worth approximately $35,000. Institutional investors and hedge funds own 87.15% of the company’s stock.
IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Article: Cost of Capital
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.